In type 2 diabetes and obesity, the levels of pro-inflammatory cytokines are increased; this inhibits the synthesis and plasma levels of adiponectin, thus decreasing its action to inhibit insulin resistance. Here, ADIPOQ is linked to Insulin resistance.